ipsogen WT1 ProfileQuant Kit CE

For quantitative detection of Wilm’s tumor (WT1) gene transcripts using real-time PCR

Features

Highly sensitive and accurate quantitative assay
Performance optimized by ELN consortium of experts
Compliance with EU IVD Directive 98/79/EC
Easy workflow with ready-to-use solutions

Product Details

The ipsogen WT1 ProfileQuant Kit is an in vitro molecular diagnostic kit for real-time PCR on the Rotor-Gene Q or other real-time PCR instruments. The kit provides reagents optimized for reliable and sensitive detection and quantification of Wilm's tumor (WT1) gene transcripts, relative to ABL control gene expression, in total RNA isolated from patients with acute myeloid leukemia (AML). The results obtained are intended to aid monitoring of early treatment response and for minimal residual disease (MRD).

Performance

To ensure highest sensitivity, the ipsogen WT1 ProfileQuant Kit has been optimized to detect Wilm's tumor (WT1) and ABL gene transcripts and uses prediluted plasmid standards and primers and probe mixes (see figures Accurate detection of Wilm's tumor plasmid standards and Reliable detection of ABL plasmid standards).

See figures

Accurate detection of Wilm’s tumor plasmid standards.

Reliable detection of ABL plasmid standards.

Principle

The ipsogen WT1 ProfileQuant Kit is a ready-to-use kit for the detection of Wilm's tumor (WT1) gene transcripts using real-time PCR. The kit is based on the amplification and quantification of specific Wilm's tumor (WT1) gene transcripts, relative to ABL control gene expression, in total RNA isolated from patients with acute myeloid leukemia (AML). The kit provides high levels of specificity, sensitivity, and reproducibility. The ipsogen WT1 ProfileQuant Kit includes specific plasmids and primers and probe mixes for WT1 and ABL (see figures WT1 gene transcript and ABL control gene transcript). Included are 5 standard dilutions for Wilm's tumor (WT1) and 3 standard dilutions for ABL. Use of the standards enables accurate quantification of transcripts. These components have been validated together in the context of a collaborative study led by a group of experts from the European Leukemia Net (ELN) consortium.

See figures

WT1 gene transcript.

ABL control gene transcript.

Procedure

The first step is reverse transcription of total RNA in a sample into cDNA. The second step is the amplification of cDNA by real-time PCR. Using the ipsogen WT1 ProfileQuant Kit allows detection and quantification of Wilm's tumor (WT1) and ABL gene transcripts. Simply start the reaction using the optimized protocols described in the kit handbook.

Applications

The ipsogen WT1 ProfileQuant Kit enable sensitive and reliable detection and quantification of Wilm's tumor (WT1) gene transcripts, relative to ABL control gene expression, for in vitro diagnostic use.